Log in

NASDAQ:TNDMTandem Diabetes Care Stock Price, Forecast & News

$79.36
+2.02 (+2.61 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$75.26
Now: $79.36
$80.68
50-Day Range
$67.38
MA: $81.18
$90.99
52-Week Range
$43.69
Now: $79.36
$92.37
Volume1.54 million shs
Average Volume1.39 million shs
Market Capitalization$4.77 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.59
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 Insulin Delivery System with Basal-IQ Technology; t:slim X2 with G5 Integration; and Tandem Device Updater that allows users to update their pump's software. In addition, the company offers t:connect diabetes management application, a cloud-based data management application, which provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; and various pump accessories. Its products in development include t:slim X2 with control IQ technology; t:sport insulin delivery system; and connected (mobile) health offerings. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.
Read More
Tandem Diabetes Care logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.48 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TNDM
CUSIPN/A
Phone858-366-6900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$362.30 million
Book Value$3.30 per share

Profitability

Net Income$-24,750,000.00

Miscellaneous

Employees1,043
Market Cap$4.77 billion
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive TNDM News and Ratings via Email

Sign-up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter.

Tandem Diabetes Care (NASDAQ:TNDM) Frequently Asked Questions

How has Tandem Diabetes Care's stock been impacted by COVID-19 (Coronavirus)?

Tandem Diabetes Care's stock was trading at $66.33 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TNDM shares have increased by 19.6% and is now trading at $79.36. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Tandem Diabetes Care?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 6 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Tandem Diabetes Care.

When is Tandem Diabetes Care's next earnings date?

Tandem Diabetes Care is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Tandem Diabetes Care.

How were Tandem Diabetes Care's earnings last quarter?

Tandem Diabetes Care Inc (NASDAQ:TNDM) issued its quarterly earnings results on Thursday, April, 30th. The medical device company reported ($0.25) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.18) by $0.07. The medical device company had revenue of $97.90 million for the quarter, compared to the consensus estimate of $84.49 million. Tandem Diabetes Care had a negative net margin of 4.22% and a negative return on equity of 9.39%. Tandem Diabetes Care's quarterly revenue was up 49.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.40) earnings per share. View Tandem Diabetes Care's earnings history.

When did Tandem Diabetes Care's stock split? How did Tandem Diabetes Care's stock split work?

Shares of Tandem Diabetes Care reverse split on the morning of Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.

What guidance has Tandem Diabetes Care issued on next quarter's earnings?

Tandem Diabetes Care issued an update on its second quarter 2020 After-Hours earnings guidance on Thursday, April, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $85 million, compared to the consensus revenue estimate of $85.26 million.

What price target have analysts set for TNDM?

13 brokerages have issued 12 month price targets for Tandem Diabetes Care's stock. Their forecasts range from $75.00 to $102.00. On average, they expect Tandem Diabetes Care's share price to reach $88.00 in the next year. This suggests a possible upside of 10.9% from the stock's current price. View analysts' price targets for Tandem Diabetes Care.

Has Tandem Diabetes Care been receiving favorable news coverage?

News headlines about TNDM stock have trended negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Tandem Diabetes Care earned a coverage optimism score of -2.8 on InfoTrie's scale. They also assigned media headlines about the medical device company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutTandem Diabetes Care.

Who are some of Tandem Diabetes Care's key competitors?

What other stocks do shareholders of Tandem Diabetes Care own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Square (SQ), Verizon Communications (VZ), Crispr Therapeutics (CRSP) and Roku (ROKU).

Who are Tandem Diabetes Care's key executives?

Tandem Diabetes Care's management team includes the following people:
  • Mr. Kim D. Blickenstaff, Exec. Chairman (Age 67)
  • Mr. John F. Sheridan, Pres & CEO (Age 64)
  • Mr. Brian B. Hansen, Exec. VP & Chief Commercial Officer (Age 51)
  • Ms. Leigh A. Vosseller, Exec. VP, CFO & Treasurer (Age 46)
  • Mr. Manuel Jaime, Sr. VP of Technology & Digital Health

What is Tandem Diabetes Care's stock symbol?

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

Who are Tandem Diabetes Care's major shareholders?

Tandem Diabetes Care's stock is owned by many different retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (11.29%), BlackRock Inc. (7.33%), Invesco Ltd. (2.77%), Federated Hermes Inc. (2.37%), State Street Corp (2.18%) and Brown Capital Management LLC (1.85%). Company insiders that own Tandem Diabetes Care stock include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Richard P Valencia and Susan Morrison. View institutional ownership trends for Tandem Diabetes Care.

Which major investors are selling Tandem Diabetes Care stock?

TNDM stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management LLC, TimesSquare Capital Management LLC, Deutsche Bank AG, Redmile Group LLC, Balyasny Asset Management LLC, Ardevora Asset Management LLP, Waddell & Reed Financial Inc., and Emerald Advisers LLC. Company insiders that have sold Tandem Diabetes Care company stock in the last year include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, and Leigh Vosseller. View insider buying and selling activity for Tandem Diabetes Care.

Which major investors are buying Tandem Diabetes Care stock?

TNDM stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Invesco Ltd., Russell Investments Group Ltd., Brown Capital Management LLC, Driehaus Capital Management LLC, Pictet Asset Management Ltd., Jennison Associates LLC, and BlackRock Inc.. View insider buying and selling activity for Tandem Diabetes Care.

How do I buy shares of Tandem Diabetes Care?

Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tandem Diabetes Care's stock price today?

One share of TNDM stock can currently be purchased for approximately $79.36.

How big of a company is Tandem Diabetes Care?

Tandem Diabetes Care has a market capitalization of $4.77 billion and generates $362.30 million in revenue each year. The medical device company earns $-24,750,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis. Tandem Diabetes Care employs 1,043 workers across the globe.

What is Tandem Diabetes Care's official website?

The official website for Tandem Diabetes Care is www.tandemdiabetes.com.

How can I contact Tandem Diabetes Care?

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company can be reached via phone at 858-366-6900 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.